Finance

Lists
BEAM:BMV
Beam Therapeutics Inc
MX$436.81
-6.58%
(-30.79) 1D
Jul 28, 8:56:54 AM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for BEAM...
Mkt. cap
2.76B
Avg. vol.
61.00
Volume
0.00
52-wk high
MX$663.44
52-wk low
MX$300.57
No. of employees
540
Mkt. cap
2.76B
Avg. vol.
61.00
Volume
0.00
52-wk high
MX$663.44
52-wk low
MX$300.57
No. of employees
540
News stories
From web sources and news partners
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc
CEOJohn Evans
Employees540
Founded2017
Headquarters-
SectorBiotechnology
Websitebeamtx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
9.70M
114.11M
31.74M
490.00K
Cost of goods sold
109.77M
99.28M
104.52M
95.10M
Cost of revenue
109.77M
99.28M
104.52M
95.10M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.74M
32.28M
34.43M
31.95M
Operating expense
26.74M
32.28M
34.43M
31.95M
Total operating expenses
136.51M
131.55M
138.95M
127.04M
Operating income
-126.81M
-17.44M
-107.22M
-126.55M
Other non operating income
8.55M
50.00K
2.50M
-4.20M
EBT including unusual items
-112.73M
244.30M
-94.32M
-122.68M
EBT excluding unusual items
-118.26M
248.39M
-94.85M
-123.27M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-112.73M
244.30M
-94.32M
-122.68M
Net profit margin
-1,162.38%
214.09%
-297.18%
-25,036.33%
Earnings per share
-1.10
2.33
-0.91
-1.18
Interest and investment income
-
10.64M
9.87M
7.49M
Interest expense
-
-
-
-
Net interest expenses
-
10.64M
9.87M
7.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
-121.25M
-11.78M
-101.61M
-121.14M
Gain or loss from assets sale
-
-
-
44.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps